Recommended Non-HDL-C Target Values
For adults with very high cardiovascular risk (including those with established atherosclerotic cardiovascular disease), target non-HDL-C should be <100 mg/dL (2.6 mmol/L), and for those at high risk, target <130 mg/dL (3.4 mmol/L). 1
Risk-Stratified Targets
The 2016 ESC/EAS guidelines provide the clearest framework for non-HDL-C targets based on cardiovascular risk stratification 1:
Very High-Risk Patients
- Non-HDL-C goal: <100 mg/dL (2.6 mmol/L)
- This includes patients with:
- Established ASCVD (prior MI, ACS, stroke, TIA, PAD, coronary revascularization)
- Diabetes with target organ damage or multiple risk factors
- Severe chronic kidney disease
High-Risk Patients
- Non-HDL-C goal: <130 mg/dL (3.4 mmol/L)
- This includes patients with:
- Markedly elevated single risk factors
- Diabetes without target organ damage
- Moderate chronic kidney disease
Practical Calculation
Non-HDL-C is easily calculated as: Total Cholesterol minus HDL-C
This simple calculation captures all atherogenic lipoproteins (VLDL, IDL, LDL, and remnant particles) without requiring fasting samples 1, 2.
Why Non-HDL-C Matters
Non-HDL-C provides superior cardiovascular risk prediction compared to LDL-C alone, particularly in patients with:
- Hypertriglyceridemia (triglycerides ≥150 mg/dL): In these patients, calculated LDL-C underestimates atherogenic particle burden, while non-HDL-C captures the additional risk from triglyceride-rich remnant particles 3, 4
- Atherogenic dyslipidemia: The combination of elevated triglycerides, low HDL-C, and small dense LDL particles 5
- Metabolic syndrome and type 2 diabetes: Where remnant cholesterol contributes significantly to residual cardiovascular risk 1
Relationship to LDL-C Targets
A practical rule: Non-HDL-C target = LDL-C target + 30 mg/dL 2
- If LDL-C target is <70 mg/dL → Non-HDL-C target is <100 mg/dL
- If LDL-C target is <100 mg/dL → Non-HDL-C target is <130 mg/dL
Clinical Caveats
Important pitfall: Even when LDL-C appears controlled at <70 mg/dL, approximately 11-12% of patients with ASCVD still have elevated remnant cholesterol (≥0.65 mmol/L or ~25 mg/dL), particularly when triglycerides are ≥150 mg/dL 3. This represents residual cardiovascular risk not addressed by LDL-C lowering alone.
Ethnic considerations: Southeast Asian populations, particularly Malays, demonstrate higher remnant cholesterol concentrations across all LDL-C levels compared to Chinese and Indian populations, especially with concurrent hypertriglyceridemia 3. This reinforces the importance of non-HDL-C monitoring in diverse populations.
Treatment Intensification
When non-HDL-C remains above goal despite statin therapy achieving LDL-C targets:
- Add ezetimibe as first-line combination therapy 1
- Consider fibrates specifically for patients with atherogenic dyslipidemia (high triglycerides, low HDL-C) 5
- PCSK9 inhibitors for very high-risk patients not at goal with maximal statin plus ezetimibe 1
The 2026 ACC/AHA guidelines now emphasize non-HDL-C alongside LDL-C for both screening and treatment escalation decisions, reflecting its superior ability to capture total atherogenic lipoprotein burden 6.